Tigecycline

被引:272
作者
Pankey, GA [1 ]
机构
[1] Ochsner Clin Fdn, New Orleans, LA 70121 USA
关键词
glycylcyclines; resistance; in vitro susceptibility; new antibiotics;
D O I
10.1093/jac/dki248
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
New antimicrobial agents are urgently needed for clinical use due to the increasing prevalence and spread of multidrug-resistant bacteria that are commonly responsible for serious and life-threatening diseases. The need to develop new agents that effectively overcome existing mechanisms of resistance displayed by bacteria resistant to currently available drugs has become paramount. Tigecycline, the first in a new class of antimicrobials, the glycylcyclines, is an analogue of minocycline with additional properties that negate most mechanisms mediating resistance to the tetracyclines. In vitro testing has revealed that tigecycline has activity against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae and many species of multidrug-resistant Gram-negative bacteria, although resistance to tigecycline by Pseudomonas aeruginosa and reduced susceptibility among Proteus species do occur. Tigecycline is being evaluated in multicentre Phase III clinical trials for therapy of many serious and life-threatening infections in which multidrug-resistant bacterial organisms may be found. Tigecycline appears to hold promise as a novel expanded spectrum antibiotic.
引用
收藏
页码:470 / 480
页数:11
相关论文
共 87 条
[1]  
[Anonymous], 43 INT C ANT AG CHEM
[2]  
APPELBAUM PC, 2003, 41 ANN M INF DIS SOC, P57
[3]   Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA [J].
Bauer, G ;
Berens, C ;
Projan, SJ ;
Hillen, W .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (04) :592-599
[4]   In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain [J].
Betriu, C ;
Rodríguez-Avial, I ;
Sánchez, BA ;
Gómez, M ;
Alvarez, J ;
Picazo, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :892-895
[5]   In vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae:: Mechanisms of macrolide and tetracycline resistance [J].
Betriu, C ;
Culebras, E ;
Rodríguez-Avial, I ;
Gómez, M ;
Sánchez, BA ;
Picazo, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (01) :323-325
[6]   Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia [J].
Betriu, C ;
Rodríguez-Avial, I ;
Sánchez, BA ;
Gómez, M ;
Picazo, JJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (05) :758-759
[7]   In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases [J].
Biedenbach, DJ ;
Beach, ML ;
Jones, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2001, 40 (04) :173-177
[8]   In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria [J].
Boucher, HW ;
Wennersten, CB ;
Eliopoulos, GM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) :2225-2229
[9]   Determining incidence of extended spectrum β-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries:: the PEARLS study 2001-2002 [J].
Bouchillon, SK ;
Johnson, BM ;
Hoban, DJ ;
Johnson, JL ;
Dowzicky, MJ ;
Wu, DH ;
Visalli, MA ;
Bradford, PA .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 24 (02) :119-124
[10]   Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center [J].
Bozdogan, B ;
Esel, D ;
Whitener, C ;
Browne, FA ;
Appelbaum, PC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (05) :864-868